Now that Definium Therapeutics Inc. (DFTX) has reported positive results from its Phase 3 Emerge trial, greater clarity has emerged around the clinical profile and potential of its lead investigational asset, DT120 Orally Disintegrating Tablet.
Emerge is the company's first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 ODT 100 mcg in adults with major depressive disorder (MDD).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com